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Summary
Background Clostridium difficile infection causes severe complications and frequently recurs. An extended-pulsed 
fidaxomicin regimen might facilitate sustained clinical cure by prolonging C difficile suppression and supporting gut 
microbiota recovery. We aimed to compare clinical outcomes of extended-pulsed fidaxomicin with standard 
vancomycin.
Methods In this randomised, controlled, open-label, superiority study, we recruited hospitalised adults aged 60 years 
and older with confirmed C difficile infection at 86 European hospitals. Patients were randomly assigned (1:1) using an 
interactive web response system to receive extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1–5, 
then once daily on alternate days on days 7–25) or vancomycin (125 mg oral capsules, four times daily on days 1–10), 
stratified by baseline C difficile infection severity, cancer presence, age (≥75 years vs <75 years), and number of previous 
C difficile infection occurrences. The primary endpoint was sustained clinical cure 30 days after end of treatment 
(day 55 for extended-pulsed fidaxomicin and day 40 for vancomycin), assessed in all randomised patients who met the 
inclusion criteria and received at least one dose of study medication (modified full analysis set). Adverse events were 
assessed in all patients who received at least one dose of study drug. The study is registered with ClinicalTrials.gov, 
number NCT02254967.
Findings Between Nov 6, 2014, and May 5, 2016, 364 patients were enrolled and randomly assigned to receive extended-
pulsed fidaxomicin or vancomycin. 362 patients received at least one dose of study medication (181 in each group). 
124 (70%) of 177 patients in the modified full analysis set receiving extended-pulsed fidaxomicin achieved sustained 
clinical cure 30 days after end of treatment, compared with 106 (59%) of 179 patients receiving vancomycin (difference 
11% [95% CI 1·0–20·7], p=0·030; odds ratio 1·62 [95% CI 1·04–2·54]). Incidence of treatment-emergent adverse 
events did not differ between extended-pulsed fidaxomicin (121 [67%] of 181) and vancomycin (128 [71%] of 181) 
treatment arms. One death in the vancomycin arm was considered by the investigator to be related to study drug. 
Interpretation Extended-pulsed fidaxomicin was superior to standard-dose vancomycin for sustained cure of C difficile 
infection, and, to our knowledge, extended-pulsed fidaxomicin recurrence rates in this study are the lowest observed 
in a randomised clinical trial of antibiotic treatment for C difficile infection.
Funding Astellas Pharma, Inc.
Introduction
Clostridium difficile is the leading cause of infectious 
health-care-associated diarrhoea in developed countries.1 
C difficile infection is particularly serious in older 
individuals, in whom it is associated with severe infection 
and complications, including recurrence and death.2–4
Prevention of recurrence of C difficile infection has 
been identified as a key unmet need.5 Recurrence is 
estimated to occur in up to 25% of patients treated with 
metronidazole or vancomycin,5,6 is associated with a 
substantial health-care burden,6 and is a particular 
problem in high-risk individuals.7 Previous 
administration of antimicrobials typically results in 
disruption of the colonic microbiota, preceding C difficile 
colonisation.8,9 Recurrence is thought to be a consequence 
of delayed recovery of this previously disrupted 
microbiota during C difficile infection therapy.8 Although 
oral vancomycin is the standard of care for severe 
C difficile infection,3 this drug has a substantial 
deleterious effect on the intestinal bacterial microbiota.10,11
The narrow-spectrum macrocyclic antibiotic fidaxo-
micin showed efficacy and tolerability for treatment of 
C difficile infection when administered as a standard 
regimen (200 mg orally twice daily for 10 days), and is 
non-inferior to standard vancomycin (125 mg orally four 
times daily for 10 days) in achieving initial clinical 
cure.12,13 Fidaxomicin is better able to preserve the gut 
microbiota than is vancomycin,10 which might explain 
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the well-documented reduced C difficile infection 
recurrence (about 15%) and improved sustained clinical 
cure (about 75%) with fidaxomicin compared with 
vancomycin (about 27% for C difficile infection recurrence 
and 64% for sustained clinical cure).12,13
Evidence from a validated in-vitro human gut model 
suggests that an extended-pulsed fidaxomicin regimen, 
which extends 20 fidaxomicin doses over a longer time 
period after initial daily dosing, might allow persistence 
of fidaxomicin at above inhibitory concentrations, thus 
prolonging suppression of C difficile, and simultaneously 
facilitating microbiota recovery.14 Consequently, 
extended-pulsed fidaxomicin is hypothesised to show 
equivalent efficacy to vancomycin in resolving C difficile 
infection. This drug regimen might also have the 
potential to reduce C difficile infection recurrence beyond 
that documented for standard fidaxomicin and increase 
sustained clinical cure.
We aimed to assess clinical outcomes of 
extended-pulsed fidaxomicin compared with vancomycin, 
with a primary efficacy endpoint of sustained clinical 
cure of C difficile infection 30 days after the end of 
treatment, in a microbiota-sparing strategy.
Methods
Study design and patients
We did a phase 3b/4, randomised, controlled, parallel, 
superiority, open-label trial at 86 hospitals in 21 European 
countries. Hospitalised patients were eligible for 
inclusion if they were aged 60 years and older with 
clinically confirmed C difficile infection, defined by either 
more than three unformed bowel movements or at least 
200 mL unformed stool (for patients with rectal collection 
devices) in the 24 h before randomisation, in addition to 
presence of C difficile toxin A or B in stool within 48 h of 
randomisation by local laboratory C difficile infection 
toxin test. Key exclusion criteria included C difficile 
infection therapy for more than 1 day within the past 48 h 
and more than two previous C difficile infection episodes 
within 3 months of enrolment (see appendix for full list 
of exclusion criteria). Before the first patient was enrolled, 
there was a country-specific protocol amendment in 
Research in context
Evidence before this study
Metronidazole and vancomycin have been the mainstays of 
Clostridium difficile infection treatment for several decades, with 
vancomycin efficacy superior to that of metronidazole. 
We searched PubMed for articles published in any language up 
to March 6, 2017, using the terms “Clostridium difficile infection” 
and “recurrence”. We identified several studies and reviews that 
reported recurrence rates of up to 25%. We noted advanced age 
as a risk factor for C difficile infection recurrence and adverse 
outcomes following treatment. In fidaxomicin phase 3 
registration studies, more than half of patients were at least 
60 years of age. These studies were the first to show that 
fidaxomicin was non-inferior to vancomycin for clinical cure, 
but also associated with a reduction in C difficile infection 
recurrence compared with vancomycin. Adjunctive therapy 
with the monoclonal antibody bezlotoxumab plus standard of 
care showed a reduction in C difficile infection recurrence 
compared with placebo at 12 weeks post-infusion. In-vitro gut 
model evidence supports the potential benefits of an 
extended-pulsed fidaxomicin treatment regimen with respect 
to rapid clearance of C difficile while simultaneously supporting 
recovery of microbiota that are important for subsequent 
colonisation resistance. Evidence for alternative fidaxomicin 
dosing strategies, including chaser and pulsed regimens for 
recurrent C difficile infection, is limited to small case series, as is 
evidence for pulsed regimens of vancomycin.
Added value of this study
This phase 3b/4 study shows superiority of extended-pulsed 
fidaxomicin over standard vancomycin in achieving sustained 
clinical cure of C difficile infection in an older patient population. 
Addition of a pulsed fidaxomicin dosing period did not 
adversely affect rates of initial clinical cure and resulted in 
reduced C difficile infection recurrence rates compared with 
vancomycin. The recurrence rate with extended-pulsed 
fidaxomicin treatment, monitored over 90 days, is the lowest 
reported to our knowledge in a randomised controlled trial of 
C difficile infection antibiotic treatment. Furthermore, 
disease-free survival was higher in extended-pulsed fidaxomicin 
patients compared with patients receiving vancomycin. 
Addition of novel exploratory microbiology endpoints also 
allows interpretation of microbiome diversity, for the first time 
to our knowledge, in a C difficile infection-targeting antibiotic 
randomised controlled trial. The shift in bacterial diversity up to 
day 55 was greater in extended-pulsed fidaxomicin patients 
compared with vancomycin patients, which supports the 
hypothesis that extended-pulsed fidaxomicin facilitates 
recovery of the microbiota during treatment. Sustained efficacy 
with the extended-pulsed fidaxomicin regimen was achieved 
with no increase in treatment costs and no detriment to safety 
compared with standard-regimen vancomycin and fidaxomicin.
Implications of all the available evidence
Prevention of recurrence of C difficile infection is recognised as a 
key unmet clinical need, particularly in high-risk populations, 
such as older patients. The EXTEND study addresses sustained 
cure as a primary measure of treatment success in a high-risk 
patient population, with recurrence monitored up to day 90. 
To our knowledge, this study provides the first clinical evidence 
for extended-pulsed fidaxomicin as an efficacious and 
well-tolerated treatment option for C difficile infection. 
Available in-vitro and clinical evidence suggests that the 
sparing effect of fidaxomicin on the gut microbiota might 
contribute to observed treatment outcomes.
See Online for appendix
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Germany at the request of the local ethics committee 
because of concerns over potential fidaxomicin 
overabsorption in patients with inflammatory bowel 
disease. Thus, patients with inflammatory bowel disease 
were also excluded from the study. Institutional review 
boards at each site approved the study protocol and 
amendments. Patients provided written informed 
consent.
Randomisation and masking
Patients were centrally randomly assigned (1:1), using an 
interactive web response system, to receive extended-
pulsed fidaxomicin or vancomycin. Random isation was 
stratified by baseline C difficile infection severity (severe 
or non-severe; severe defined as leucocyte count 
>15 × 10⁹ cells per L or rise in serum creatinine 
[>50% above a patient’s normal level] or albumin 
<30 g/L), presence or absence of cancer (defined as 
diagnosis of cancer within 6 months of the study or 
ongoing therapy for cancer treatment), age (≥75 years or 
<75 years), or number of previous C difficile infection 
occurrences (zero, one, or two) in the 3 months before 
study entry, with a block size of four, which was agreed 
before entry. Patients were recruited by the study 
investigators at sites in Europe, Russia, and Turkey.
Patients could participate in pharmacokinetic and 
microbiome (16S rRNA sequencing) substudies to 
analyse the concentration of fidaxomicin in blood 
(plasma), and the microbiome profile in stool samples.
Procedures
Presence of C difficile infection was locally confirmed at 
the screening visit. Patients received commercially 
available oral fidaxomicin 200 mg film-coated tablets 
(Astellas Pharma Europe, Leiden, Netherlands) twice 
daily on days 1–5, then once daily on alternate days on 
days 7–25 (extended-pulsed fidaxomicin), or commercially 
available oral vancomycin 125 mg capsules (Xellia 
Pharmaceuticals, Copenhagen, Denmark), four times 
daily on days 1–10.
At the test of cure visit on day 12 for vancomycin and 
day 12 or day 27 for extended-pulsed fidaxomicin, 
C difficile infection assessments, severity score, and 
clinical response were assessed. Clinical response was 
based on European Society of Clinical Microbiology and 
Infectious Diseases criteria.3 Sustained clinical cure, 
defined as clinical response at test of cure and no 
C difficile infection recurrence, was determined on days 
40, 55, and 90 (end of follow-up). All other cases were 
deemed treatment failures for sustained clinical cure.
For patients with clinical response at test of cure, 
recurrence of C difficile infection was defined as return of 
diarrhoea after test of cure to an extent (according to the 
frequency of unformed bowel movements) that was 
greater than the frequency recorded on day 10 for the 
vancomycin arm or day 25 for the extended-pulsed 
fidaxomicin arm, confirmed by a local C difficile infection 
test positive for toxin A or B and requiring further 
therapy. Recurrence was assessed up to day 90.
Stool samples were collected for all patients at 
screening (day 0) and, in the case of treatment failure or 
C difficile infection recurrence, stool samples underwent 
microbiological testing at a central laboratory (LGC, 
Fordham, UK). Samples were tested for the presence of 
C difficile toxin A or B using a qualitative ELISA, and 
bacterial, parasitic, or viral enteric pathogens, including 
C difficile, according to established methods (PCR-based 
multiplex test; BioFire FilmArray Gastrointestinal Panel, 
Biomérieux, Marcy-l’Étoile, France).
Pharmacokinetic assessments were done on days 
5, 12, and 27. Stool samples for overall microbial diversity 
(microbiota substudy) analysis were collected on days 
0, 5, 12, 27, 40, and 55, and at unscheduled visits for 
treatment failure or C difficile infection recurrence, and 
were tested at LGC Genomics, Berlin, Germany. Total 
bacterial DNA was extracted and the 16S rRNA gene 
sequenced (Illumina MiSeq V3, Illumina, San Diego, 
CA, USA) to measure changes in bacterial diversity 
following treatment with extended-pulsed fidaxomicin or 
vancomycin (appendix). The Shannon index of α diversity 
was calculated using Qiime version 1.9.0.
Patients were followed up at least every 2 weeks to 
check for C difficile infection recurrence, adverse events, 
and concomitant medication. If the patient was 
discharged from hospital, this follow-up might have been 
done by telephone. Information was collected if patients 
died, were readmitted to hospital, or if they received 
treatment or diagnostic procedures as either an inpatient 
or outpatient (resource utilisation).
Outcomes
The primary efficacy endpoint was sustained clinical cure 
of C difficile infection at 30 days after end of treatment 
(day 40 for vancomycin and day 55 for extended-pulsed 
fidaxomicin). Secondary endpoints were sustained 
clinical cure of C difficile infection at days 40, 55, and 
90 for both treatment groups; clinical response of 
C difficile infection at day 12 and at 2 days after end of 
treatment (day 12 or day 27 for both vancomycin and 
extended-pulsed fidaxomicin); rate of relapse at day 90 as 
determined by whole genome sequencing of C difficile 
isolates from patients who had documented recurrence 
after test of cure; time to resolution of diarrhoea from the 
start of treatment, sustained to test of cure (ie, time of the 
last unformed bowel movement the day before the first of 
two consecutive days of ≤3 unformed bowel movements, 
>50% reduction in number of stools, or >75% reduction 
in liquid stool volume); recurrence of C difficile infection 
at days 40, 55, and 90; time to C difficile infection 
recurrence after end of treatment (for patients with 
clinical response); disease-free survival after day 
10 (for patients with clinical response); incidence of 
mortality and severity of adverse events at day 90; health-
related quality of life up to day 55; and readmission and 
For Qiime software see 
http://qiime.org/
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length of hospital stay at day 90. At the time of writing, 
data were not available on health-related quality of life, 
readmission, or length of stay, and these data will be 
reported separately. Exploratory endpoints included the 
number and volume of unformed bowel movements per 
day, and microbial diversity in stool samples. Safety was 
assessed from the first day of study treatment (day 1) to 
the end of study visit (day 90).
Figure 1: Trial profile
39 excluded due to screening failure
183 assigned to extended-pulsed fidaxomicin
 181 received at least one dose (safety analysis set)
 2 did not receive treatment
177 included in modified full analysis set
 127 included in per-protocol set
 27 microbiologically evaluable
            13 samples for paired microbiome analysis/
                  Shannon index
              2 samples for paired initial/recurrence samples
                 for whole genome sequencing  
 
38 discontinued treatment
 8 adverse events
 13 died
 4 lack of efficacy
 4 lost to follow-up
 6 withdrawal by patient
 2 physician decision
 1 non-compliance with study drug




142 attended day 40 visit
4 discontinued 
 2 died




 1 withdrawal by patient
403 patients assessed for eligibility
364 enrolled
181 assigned to vancomycin
 181 received at least one dose (safety analysis set) 
179 included in modified full analysis set
 125 included in per-protocol set
 22 microbiologically evaluable
              9 samples for paired microbiome analysis/
                  Shannon index
              9 samples for paired initial/recurrence samples
                 for whole genome sequencing  
 
15 discontinued treatment
 2 adverse events
 4 died
 4 lack of efficacy
 4 withdrawal by patient
 1 other
137 attended day 55 visit
21 discontinued
 12 died
   4 lost to follow-up
    3 withdrawal by patient
    1 physician decision
    1 other
166 completed treatment
145 attended day 40 visit
8 discontinued
  7 died





 3 lost to follow-up
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Adverse events were recorded at each study visit and 
assessed by a local investigator for severity and 
relationship to study drug. Adverse events of mild 
intensity were defined as those that did not disrupt 
normal daily activities.
Statistical analysis
To detect a difference between extended-pulsed fidaxomicin 
and vancomycin in relation to the primary endpoint, a 
maximum sample size of 346 patients (173 per arm) 
provided approximately 90% power at a two-sided overall 
significance level of 0·05. Assumptions were based on 
sustained clinical cure rates of 85% for extended-pulsed 
fidaxomicin and 70% for vancomycin (corresponding to an 
odds ratio [OR] of 2·43),12,13 accounting for an interim 
analysis conducted after about 55% of patients with 
confirmed C difficile infection had completed the primary 
endpoint assessment. We planned to recruit an additional 
18 patients to allow for incorrect inclusion of patients 
without positive C difficile culture confirmed at baseline.
Descriptive statistics are provided for continuous and 
categorical variables. All null hypotheses assumed no 
treatment difference and all alternative hypotheses were 
two-sided. Sustained clinical cure at 30 days after end of 
treatment was summarised by treatment group and the 
difference between the two treatment arms was compared 
across strata using the Cochran-Mantel-Haenszel test, 
adjusting for baseline stratification factors. Similar analyses 
were done for the secondary endpoints of sustained clinical 
cure at days 40, 55, and 90, clinical response (at day 12 and 
at 2 days after the end of treatment), and recurrence of 
C difficile infection (at days 40, 55, and 90). The significance 
level for comparison of the primary endpoint was 0·0425 for 
the final analysis. Additionally, multivariate analysis 
(logistic regression), which included treatment arm and 
baseline stratification factors as covariates, was done. If the 
primary endpoint differed significantly between treatment 
arms, then adjusted p values were obtained using the 
Hochberg procedure for endpoints of sustained clinical 
cure at days 40, 55, and 90, clinical response at day 12, and 
rate of relapse on day 90. For the endpoints time to C difficile 
infection recurrence after end of treatment, disease-free 
survival after day 10, and time to resolution of diarrhoea, 
the Kaplan-Meier method was used for the analyses and 
the stratified Wilcoxon-Gehan test used to compare survival 
(Kaplan-Meier) estimates. Time to resolution of diarrhoea 
was analysed using the Cox proportional hazards model, 
adjusting for treatment arm and baseline stratification 
factors. Differences in bacterial diversity were analysed 
using paired t tests.
Two study populations, the modified full analysis set 
and per-protocol set, were analysed for primary and 
secondary endpoints. The modified full analysis set 
comprised all randomised patients who met inclusion 
criteria and received at least one dose of study medication, 
and was the primary analysis set for efficacy. The per- 
protocol set comprised all patients in the modified full 
analysis set who had no major protocol deviations before 
assessment of the primary clinical endpoint and received 
at least 70% of the study treatment (appendix). The safety 
analysis set included all randomised patients who 
received at least one dose of study medication.
All analyses were done using SAS version 9.3. EXTEND 
is registered with ClinicalTrials.gov, number NCT02254967. 
An independent data monitoring committee continually 
reviewed drug safety.
Role of the funding source
The study sponsor was involved in all stages of the study, 
including manuscript development. The corresponding 







Female 107 (60%) 100 (56%)
Male 70 (40%) 79 (44%)
Race*
White 149 (84%) 153 (85%)
Missing 28 (16%) 26 (15%)
Median age, years (IQR) 75 (69–83) 75 (67–82)
Number of unformed bowel movements per day
Mean (SD) 6·8 (4·7) 6·4 (3·4)
Median (IQR) 5 (4–7) 5 (4–7)
Clostridium difficile infection severity†
Severe 63 (36%) 67 (37%)
Non-severe 114 (64%) 112 (63%)
Number of previous C difficile infection occurrences in the past 3 months†
0 141 (80%) 140 (78%)
1 26 (15%) 29 (16%)
2 10 (6%) 10 (6%)
Cancer status†
Presence 38 (21%) 37 (21%)
Absence 139 (79%) 142 (79%)
Use of antibiotics for condition other than C difficile infection‡
Yes 128 (72%) 129 (72%)
No 49 (28%) 50 (28%)
Residential setting before study enrolment
Own residence 102 (58%) 103 (58%)
Family residence 66 (37%) 59 (33%)
Nursing home§ 4 (2%) 6 (3%)
Long-term care facility§ 1 (1%) 4 (2%)
Other 2 (1%) 7 (4%)
Missing 2 (1%) 0
Data are n (%) unless otherwise specified. *Not all study sites were permitted to 
report the race of patients, and in these cases this information was reported as 
missing. †Provided by interactive web response system at randomisation; type of 
cancer recorded only for medical history and not for analysis. ‡In the 90 days 
before the study. §A nursing home provides supportive care, whereas a long-term 
care facility provides rehabilitative care with a greater number of clinical personnel 
and facilities.
Table 1: Baseline patient characteristics (modified full analysis set)
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final responsibility for the decision to submit for 
publication.
Results
Between Nov 6, 2014, and May 5, 2016, 403 patients were 
screened for inclusion in the study. 39 patients were 
excluded due to screening failure and thus 364 patients 
were randomly assigned to receive extended-pulsed 
fidaxomicin or vancomycin (figure 1). 362 patients 
received at least one dose of study medication 
(181 received extended-pulsed fidaxomicin and 
181 received vancomycin) and were included in the safety 
analysis (figure 1). Two patients randomised to extended-
pulsed fidaxomicin did not have clinically confirmed 
C difficile and did not receive treatment.
Two patients in the vancomycin group and four in the 
extended-pulsed fidaxomicin group did not have 
confirmed C difficile infection, so were excluded from the 
modified full analysis set. Both treatment groups were 
similar regarding baseline characteristics, including age, 
C difficile infection severity, number of previous C difficile 
infection occurrences, and number of unformed bowel 
movements in the 24 h before randomisation (table 1).
For the primary efficacy endpoint, 124 (70%) of 
177 patients in the extended-pulsed fidaxomicin group 
had sustained clinical cure at 30 days after end of 
treatment compared with 106 (59%) of 179 patients who 
received vancomycin (OR 1·62 [95% CI 1·04 –2·54]; 
p=0·030, Cochran-Mantel-Haenszel test [primary 
analysis] and p=0·035, multivariate analysis; figure 2, 
table 2).
Results for the primary endpoint in the per-protocol set 
were similar to those in the modified full analysis 
set, with sustained clinical cure at 30 days after end 
of treatment higher in patients who received 
extended-pulsed fidaxomicin compared with those who 
received vancomycin (p=0·001; table 3). In the modified 
full analysis set only, multivariate analysis for sustained 
clinical cure at 30 days after end of treatment, adjusted 
for baseline stratification factors, showed that patients 
with severe C difficile infection were less likely to achieve 
sustained clinical cure than were patients with non-
severe C difficile infection (table 2). Extended-pulsed 
fidaxomicin was associated with an increased rate of 
sustained clinical cure compared with vancomycin at 
30 days after end of treatment in patients with PCR 
ribotype 027 infections (table 2). More patients in the 
extended-pulsed fidaxomicin arm than in the vancomycin 
arm achieved the secondary efficacy endpoint of 
sustained clinical cure at days 40, 55, and 90 in the 
modified full analysis set (table 2, figure 2) and per-
protocol set (table 3).
At day 12 and day 27 (2 days after end of treatment), the 
clinical response to treatment did not differ between the 
extended-pulsed fidaxomicin and vancomycin study 
arms for the modified full analysis set (table 2, figure 2) 
and the per-protocol set (table 3).
For patients who had clinical response to treatment at 
test of cure visit (day 12 for vancomycin and day 27 for 
extended-pulsed fidaxomicin), fewer patients in the 
extended-pulsed fidaxomicin than in the vancomycin 
arm had recurrence of C difficile infection at all three 
timepoints (day 40, day 55, and day 90; tables 2, 3; 
figure 2). At 30 days after end of treatment (day 55 for 
extended-pulsed fidaxomicin and day 40 for vancomycin), 
recurrence had occurred in seven (4%) patients receiving 
extended-pulsed fidaxomicin and 30 (17%) patients 
receiving vancomycin. Time to C difficile infection 
recurrence was longer after the end of treatment with 
extended-pulsed fidaxomicin than with vancomycin 
(p<0·0001; appendix).
The median time from start of treatment to resolution 
of diarrhoea appeared to favour vancomycin (censored at 
day 10, end of treatment) rather than extended-pulsed 
fidaxomicin (censored at day 25, end of treatment), 
although groups did not differ in the modified full 
analysis set (table 2) or the per-protocol set (table 3).
Most patients (127 of 137 extended-pulsed fidaxomicin 
patients and 114 of 147 vancomycin patients, of those 
who responded at test of cure) did not show symptoms 
of diarrhoea after day 10 and remained in the analysis 
until they discontinued or completed the study, after 
which they were censored. The time taken after day 
10 for the first 5% of patients in the extended-pulsed 
fidaxomicin arm to have C difficile infection recurrence 
was 47 days (95% CI 23·0–not reached), compared with 
Figure 2: Selected clinical outcomes
Bars show 95% CI. Percentage increase or decrease for extended-pulsed fidaxomicin compared with vancomycin is 
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9 days (95% CI 4·0–10·0) in the vancomycin arm. This 
overall difference in disease-free survival was significant 
(p=0·003; appendix). A hazard ratio of 0·26 (95% CI 
0·12–0·50) was determined from a Cox proportional 
hazards model, adjusted for baseline stratification 
factors. This result suggests that the hazard of C difficile 
infection recurrence at any given time after day 10 for a 
vancomycin-treated patient was approximately 
3·8-times that of an extended-pulsed fidaxomicin-
treated patient.
The mean of the Shannon index of bacterial α 
diversity in stool samples was 3·39 (SD 0·93) at day 0 
Extended-pulsed 
fidaxomicin (n=177)
Vancomycin (n=179) OR (95% CI) p value
Clinical response at day 12*
n (%) 142 (80%) 147 (82%) 0·91 (0·54–1·54) 0·721
OR by baseline stratification
Clostridium difficile infection severe vs non-severe ·· ·· 0·42 (0·24–0·72) 0·0018
Presence vs absence of cancer ·· ·· 0·72 (0·39–1·35) 0·311
Age group ≥75 years vs <75 years ·· ·· 1·13 (0·65–1·96) 0·660
Previous C difficile infection occurrences (2 vs 0) ·· ·· 1·09 (0·30–3·96) 0·898
Previous C difficile infection occurrences (1 vs 0) ·· ·· 0·88 (0·42–1.84) 0·733
Clinical response 2 days after end of treatment (day 27 for extended-pulsed fidaxomicin or day 12 for vancomycin)*
n (%) 138 (78%) 147 (82%) 0·81 (0·48–1·35) 0·399
OR by baseline stratification
C difficile infection severe vs non-severe ·· ·· 0·54 (0·31–0·92) 0·025
Presence vs absence of cancer ·· ·· 0·49 (0·27–0·88) 0·016
Age group ≥75 years vs <75 years ·· ·· 0·94 (0·55–1.62) 0·825
Previous C difficile infection occurrences (2 vs 0) ·· ·· 1·27 (0·35–4·65) 0·715
Previous C difficile infection occurrences (1 vs 0) ·· ·· 0·83 (0·41–1·72) 0·624
Time to resolution of diarrhoea
Median time (h) to resolution (95% CI) 34·0 (25·0–49·0) 22·0 (10·0–30·0) ·· 0·068
Patients with unformed bowel movements on day 5 of treatment†
0 per day 64 (40%) [n=160] 69 (41%) [n=170] ·· ··
1–2 per day 51 (32%) [n=160] 67 (39%) [n=170] ·· ··
≥3 per day 45 (28%) [n=160] 34 (20%) [n=170] ·· ··
Patients with unformed bowel movements on day 12 of treatment‡
0 per day 110 (74%) [n=148] 57 (74%) [n=77] ·· ··
1–2 per day 29 (20%) [n=148] 16 (21%) [n=77] ·· ··
≥3 per day 9 (6%) [n=148] 4 (5%) [n=77] ·· ··
Patients with unformed bowel movements on day 25 of treatment§
0 per day 115 (85%) [n=135] ·· ·· ··
1–2 per day 15 (11%) [n=135] ·· ·· ··
≥3 per day 5 (4%) [n=135] ·· ·· ··
Recurrence of C difficile infection
At day 40 3 (2%) 30 (17%) 0·09 (0·03–0·29) <0·0001
At day 55 7 (4%) 32 (18%) 0·20 (0·08–0·46) <0·0001
At day 90 11 (6%) 34 (19%) 0·29 (0·14–0·60) 0·00073
Sustained clinical cure 30 days after end of treatment
n (%) 124 (70%) 106 (59%) 1·62 (1·04–2·54) 0·030
OR by baseline stratification
C difficile infection severe vs non-severe ·· ·· 0·57 (0·36–0·91) 0·019
Presence vs absence of cancer ·· ·· 0·59 (0·35–1·01) 0·053
Age group ≥75 years vs <75 years ·· ·· 0·83 (0·53–1·30) 0·414
Previous C difficile infection occurrences (2 vs 0) ·· ·· 0·69 (0·26–1·80) 0·444
Previous C difficile infection occurrences (1 vs 0) ·· ·· 0·61 (0·33–1·11) 0·105
Sustained clinical cure 30 days after end of treatment
Presence of C difficile PCR ribotype 027¶ 20 (80%) [n=25] 9 (41%) [n=22] ·· 0·0059
Absence of C difficile PCR ribotype 027|| 104 (68%) [n=152] 97 (62%) [n=157] ·· 0·221
(Table 2 continues on next page)
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and 4·47 (0·73) at day 55 for 13 extended-pulsed 
fidaxomicin-treated patients, and 3·49 (1·23) at 
day 0 and 3·20 (1·24) at day 55 for nine vancomycin-
treated patients. The distribution of shift in Shannon 
index indicated that bacterial α diversity increased to a 
higher extent in extended-pulsed fidaxomicin-treated 
patients than in vancomycin-treated patients (median 
shift 0·83, IQR 0·51 to 1·68 vs –0·37, –0·80 to 0·79; 
figure 3) over the course of the study treatment and 
follow-up period.
Presence of C difficile and microbial pathogens other 
than C difficile was analysed by a central laboratory in 
332 samples taken at screening using a PCR-based 
multiplex test. Of these samples, 88% (292 of 332) were 
positive for C difficile and 23% (76 of 332) were positive 
for a gastrointestinal pathogen other than C difficile, of 
which enteropathogenic Escherichia coli was the most 
commonly identified (29 [9%] of 332; appendix).
Plasma pharmacokinetic analysis revealed low 
concentrations of fidaxomicin from days 5 to 25 or 
26 (sampling depended on timing of extended-pulsed 
fidaxomicin dosing), in the range 3·75–175 ng/mL at 
1–5 h after dosing. Median plasma fidaxomicin 
concentrations decreased in line with the change in 
dosing scheme. There was no accumulation of 
fidaxomicin in plasma over the extended dosing period.
Overall, the safety profile of extended-pulsed 
fidaxomicin seemed similar to that of the vancomycin 
regimen (table 4). 87 (48%) of 181 adverse events in the 
extended-pulsed fidaxomicin group and 91 (50%) of 176 
in the vancomycin group were classified as mild. Serious 
adverse events occurred in 68 (38%) extended-pulsed 
fidaxomicin-treated patients and 78 (43%) vancomycin-
treated patients. Three (2%) patients receiving extended-
pulsed fidaxomicin and six (3%) patients receiving 
vancomycin had drug-related serious adverse events. The 
drug-related serious adverse events in the extended-
pulsed fidaxomicin arm were one event (1%) each of 
pruritus, bile duct stone, and drug hypersensitivity; the 
latter two adverse events led to permanent discontinuation 
of study drug. The drug-related serious adverse events in 
the vancomycin arm were one event each of cardiac 
failure, ileus (leading to permanent discontinuation of 
study drug), treatment failure, Clostridium spp infection, 
Klebsiella spp infection, sepsis, somnolence, and eczema.
65 (18%) deaths occurred during the study, with 
29 (16%) in the extended-pulsed fidaxomicin arm and 
36 (20%) in the vancomycin arm (appendix). Only one 
death was related to study drug (as assessed by the 
investigator)—a 73-year-old woman in the vancomycin 




Vancomycin (n=179) OR (95% CI) p value
(Continued from previous page)
Sustained clinical cure
At day 40 133 (75%) 106 (59%) 2·10 (1·32–3·34) 0·0013
At day 55 124 (70%) 99 (55%) 1·91 (1·23–2·98) 0·0038
At day 90 116 (66%) 92 (51%) 1·80 (1·17–2·77) 0·0070
Clinical outcome by presence of enteric pathogen**
Sustained clinical cure 30 days after end of treatment
C difficile 103 (88%) [n=117] 86 (90%) [n=96] ·· ··
Other pathogen 39 (33%) [n=117] 37 (39%) [n=96] ·· ··
None detected 9 (8%) [n=117] 3 (3%) [n=96] ·· ··
Recurrence
C difficile 8 (4%) [n=181] 20 (11%) [n=181] ·· ··
Other pathogen 1 (1%) [n=181] 4 (2%) [n=181] ·· ··
None detected 1 (1%) [n=181] 5 (3%) [n=181] ·· ··
Treatment failure
C difficile 0 0 ·· ··
Other pathogen 0 1 (1%) [n=181] ·· ··
None detected 2 (1%) [n=181] 2 (1%) [n=181] ·· ··
Data are n (%) unless otherwise indicated. Number of patients analysed is presented in square brackets if data are missing. OR=odds ratio. *Difference between the rates 
(extended-pulsed fidaxomicin and vancomycin) and the associated 95% CI around the difference, day 12 −1·9% (−10·0 to 6·2), p=0·721 and 2 days after end of treatment 
−4·2% (−12·5 to 4·1), p=0·399. †Patients were censored at day 10 for vancomycin (240 h after start of treatment) and at day 25 for extended-pulsed fidaxomicin (600 h after 
start of treatment). ‡147 patients were not included in the analysis as they had no unformed bowel movement records provided up to day 13. §For the vancomycin arm, 
unformed bowel movement records were collected only up to day 12 (plus or minus 2 days). ¶Treatment difference 39·1 (95% CI 13·2–64·9). ||Treatment difference 
6·6 (95% CI –4·0 to 17·2). **Pathogens detected by multiplex PCR testing of faecal samples at screening in the safety analysis set, at treatment failure, Clostridium difficile 
recurrence, or unscheduled event. Other pathogens included non-C difficile bacterial, parasitic, and viral enteric pathogens, identified according to established methods 
(appendix).
Table 2: Clinical outcomes for the modified full analysis set
Articles
304 www.thelancet.com/infection   Vol 18   March 2018
Extended-pulsed 
fidaxomicin (n=124)
Vancomycin (n=125) OR (95% CI) p value
Clinical response at day 12*
n (%) 111 (90%) 109 (87%) 1·22 (0·55–2·70) 0·621
OR by baseline stratification
Clostridium difficile infection severe vs non-severe ·· ·· 0·56 (0·25–1·26) 0·160
Presence vs absence of cancer ·· ·· 0·99 (0·35–2·78) 0·985
Age group ≥75 years vs <75 years ·· ·· 0·91 (0·40–2·05) 0·818
Previous C difficile infection occurrences (2 vs 0) ·· ·· 0·96 (0·20–4·60) 0·955
Previous C difficile infection occurrences (1 vs 0) ·· ·· 1·20 (0·39–3.71) 0·754
Clinical response 2 days after end of treatment (day 27 for extended-pulsed fidaxomicin or day 12 for vancomycin)*
n (%) 116 (94%) 109 (87%) 1·97 (0·81–4·79) 0·131
OR by baseline stratification
C difficile infection severe vs non-severe ·· ·· 1·33 (0·49–3·60) 0·575
Presence vs absence of cancer ·· ·· 0·74 (0·26–2·14) 0·583
Age group ≥75 years vs <75 years ·· ·· 0·78 (0·32–1·89) 0·579
Previous C difficile infection occurrences (2 vs 0) ·· ·· 0·80 (0·16–3·90) 0·778
Previous C difficile infection occurrences (1 vs 0) ·· ·· 0·72 (0·24–2·10) 0·544
Time to resolution of diarrhoea
Median time (h) to resolution (95% CI) 28·5 (22·0–42·0) 13·0 (8·0–26·0) ·· 0·113
Patients with unformed bowel movements on day 5 of treatment†
0 per day 49 (40%) 50 (40%) ·· ··
1–2 per day 40 (32%) 54 (43%) ·· ··
≥3 per day 35 (28%) 21 (17%) ·· ··
Patients with unformed bowel movements on day 12 of treatment‡
0 per day 91 (73%) 45 (71%) [n=63] ·· ··
1–2 per day 25 (20%) 15 (24%) [n=63] ·· ··
≥3 per day 8 (6%) 3 (5%) [n=63] ·· ··
Patients with unformed bowel movements on day 25 of treatment§
0 per day 101 (86%) [n=117] ·· ·· ··
1–2 per day 12 (10%) [n=117] ·· ·· ··
≥3 per day 4 (3%) [n=117] ·· ·· ··
Recurrence of C difficile infection
At day 40 3 (2%) 22 (18%) 0·12 (0·04–0·41) <0·0001
At day 55 7 (6%) 23 (18%) 0·31 (0·13–0·73) 0·0032
At day 90 11 (9%) 23 (18%) 0·49 (0·23–1·04) 0·048
Sustained clinical cure 30 days after end of treatment¶
n (%), 95% CI 106 (85·5%), 79·3–91·7 83 (66·4%), 58·1–74·7 2·99 (1·52–5·90) 0·0011
OR by baseline stratification
C difficile infection severe vs non-severe ·· ·· 1·49 (0·73–3·04) 0·273
Presence vs absence of cancer ·· ·· 0·62 (0·29–1·35) 0·227
Age group ≥75 years vs <75 years ·· ·· 0·54 (0·28–1·02) 0·059
Previous C difficile infection occurrences (2 vs 0) ·· ·· 0·53 (0·18–1·63) 0·270
Previous C difficile infection occurrences (1 vs 0) ·· ·· 0·43 (0·20–0·92) 0·030
Sustained clinical cure
At day 40 113 (91%) 83 (66%) 5·83 (2·61–13·05) <0·0001
At day 55 106 (85%) 78 (62%) 3·61 (1·84–7·07) <0·0001
At day 90 100 (81%) 75 (60%) 2·71 (1·48–4·96) 0·0011
Data are n (%) unless otherwise indicated. Number of patients analysed is presented in square brackets if data are missing. OR=odds ratio. *Difference between the rates 
(extended-pulsed fidaxomicin and vancomycin) and the associated 95% CI around the difference, day 12 2·3% (−5·6 to 10·3), p=0·621 and at 2 days after end of treatment 
6·3% (−0·9 to 13·6), p=0·131. †Patients were censored at day 10 (240 h after start of treatment) for vancomycin and day 25 (600 h after start of treatment) for 
extended-pulsed fidaxomicin. ‡99 patients were not included in the analysis as they had no unformed bowel movement records provided up to day 13. §For the 
vancomycin arm, unformed bowel movement records were collected only up to day 12 (plus or minus 2 days). ¶Treatment difference 19·1 (8·7–29·4; p=0·0011).
Table 3: Clinical outcomes for the per-protocol set
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Discussion
In this multicentre, randomised C difficile infection study 
testing the concept of pulsed dosing as a microbiota-
sparing strategy, extended-pulsed fidaxomicin was 
superior to standard-dose vancomycin for the primary 
endpoint of sustained clinical cure of C difficile infection 
in patients aged 60 years and older. Crucial to the 
achievement of sustained clinical cure, the recurrence 
rate observed in the present study was lower in the 
extended-pulsed fidaxomicin arm than in the vancomycin 
arm at every visit up to day 90. The recurrence rate at 
day 90 in the extended-pulsed fidaxomicin arm (6%) was 
lower than was reported in previous randomised, 
controlled studies of standard regimens of fidaxomicin, 
vancomycin, and metronidazole.3,12,13 A recurrence rate of 
8–26%, depending on previous recurrence, was observed 
in a real-world study of fidaxomicin.16 Follow-up to day 90, 
as in our study, is unusual and gives added insight and, 
to our knowledge, such a long follow-up has only been 
reported in the registration study of the monoclonal 
antibody bezlotoxumab.17
Although the sustained clinical cure of C difficile 
infection achieved at 30 days after the end of extended-
pulsed fidaxomicin treatment in our study (70%) was 
similar to that achieved in phase 3 studies with a standard 
twice-daily, 10-day course of fidaxomicin (214 [75%] of 
287 patients;13 221 [88%] of 252 patients12), the results of 
these previous studies are not directly comparable to 
ours because of differences in study design and outcome 
criteria. Patients in EXTEND were older than were those 
in previous studies (mean 75·1 years [SD 8·7] compared 
with 61·6 years [16·9]13 and 63·4 years [18·1]12) to stress 
test the regimen, and the recurrence rate was substantially 
lower at 90 days with extended-pulsed fidaxomicin in 
EXTEND (6%) than it was at 40 days with standard 
fidaxomicin in previous phase 3 studies (39 [15%] of 
253 patients;13 28 [13%] of 221 patients12).
Patients older than 65 years have a greater relative risk 
of C difficile infection recurrence than do younger 
patients, and patients aged at least 75 years have a higher 
odds ratio for mortality before 30 days.18 The reduction in 
recurrence rates observed with extended-pulsed 
fidaxomicin compared with previous studies suggests 
potential health-care benefits beyond the studied clinical 
endpoints. In the extended-pulsed fidaxomicin regimen, 
the same number of fidaxomicin tablets is administered 
as in the standard licensed regimen, but enhanced 
outcomes are seen compared with vancomycin, 
potentially resulting in a cost-effectiveness benefit. 
Additionally, as C difficile infection recurrence has high 
cost implications, avoidance of recurrence is considered 
economically important, particularly in high-risk 
patients.19 For every seven patients treated with 
fidaxomicin, an estimated one hospital readmission for 
C difficile infection is prevented compared with patients 
treated with vancomycin.20 In our study of an older 
patient population, the number needed to treat with 
extended-pulsed fidaxomicin is estimated at 6·6, derived 
from the absolute difference in recurrence rate with 
vancomycin at a similar timepoint of 40 days. Recurrence 
rates observed in the vancomycin arm were lower than 
those previously reported in the vancomycin arm of 
fidaxomicin phase 3 registration trials.12,13 Epidemiological 
changes, differences in antimicrobial stewardship and 
infection control, and differences in the characteristics or 
treatment of the patient population might have 
contributed to this reduction in recurrence with 




Any treatment-emergent adverse event 121 (67%) 128 (71%)
Any severe treatment-emergent adverse event* 44 (24%) 56 (31%)
Any treatment-emergent adverse event related to study drug† 14 (8%) 9 (5%)
Any serious treatment-emergent adverse event‡ 68 (38%) 78 (43%)
Any treatment-emergent adverse event leading to 
discontinuation of study drug§
14 (8%) 5 (3%)
Any treatment-emergent adverse event causing death 3 (2%) 3 (2%)
Adverse event by preferred term¶
Anaemia 5 (3%) 10 (6%)
Cardiac failure 4 (2%) 10 (6%)
Constipation 10 (6%) 5 (3%)
Diarrhoea 10 (6%) 12 (7%)
Pyrexia 7 (4%) 12 (7%)
Clostridium spp infection|| 7 (4%) 24 (13%)
Pneumonia 5 (3%) 10 (6%)
Sepsis 1 (1%) 9 (5%)
Urinary tract infection 6 (3%) 12 (7%)
Data are presented as n (%). *Defined as adverse events causing inability to perform daily activities. †Possibly or 
probably related to study drug, as assessed by the investigator, or records where relationship was missing. ‡Defined as 
adverse events resulting in death, or considered to be life-threatening, requiring hospitalisation, or resulting in 
persistent or substantial disability or incapacity, congenital anomaly, or other medically important events. 
§A woman aged 79 years had drug hypersensitivity (rash and bronchospasm) of moderate intensity on treatment 
day 3. The event was considered serious and probably related to treatment. Dechallenge with enhanced-pulsed 
fidaxomicin was positive. Enhanced-pulsed fidaxomicin was permanently withdrawn. The event resolved on day 7 after 
treatment for hypersensitivity. This side-effect is noted on the fidaxomicin label.15 ¶Reported in at least 5% of patients 
in any treatment group. ||All treatment-emergent adverse advents recorded as Clostridium spp infection were 
Clostridium difficile infection. 
Table 4: Treatment-emergent adverse events
Figure 3: Distribution of shift in Shannon index of faecal microbiota 
α diversity from day 0 to day 55
Paired comparison of mean (SD) α diversity from day 0 to day 55 for 
extended-pulsed fidaxomicin was 1·08 (0·96), p=0·0015, and for vancomycin 
was -0·29 (1·25), p=0·5056. Box shows 25–75th percentile, vertical line shows 
median, and diamond shows mean. Whiskers show range.
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vancomycin in this study align with reported recurrence 
rates in a retrospective cohort study.21
In phase 3 studies, no significant difference in efficacy 
was observed between fidaxomicin and vancomycin in 
patients with PCR ribotype 027 infections.13 In our study, 
extended-pulsed fidaxomicin was associated with an 
increased rate of sustained clinical cure compared with 
vancomycin at 30 days after end of treatment in this 
patient subgroup. However, as with previous studies, 
EXTEND was not sufficiently powered to permit strong 
conclusions on differences in efficacy in patients with 
PCR ribotype 027 infections.
Vancomycin therapy is detrimental to the gut 
microbiota, with depletion of many bacterial types 
(operational taxonomic units), particularly from the 
Bacteroidetes phylum, and the proportion of several 
organisms associated with human infection, such as 
Klebsiella spp, Escherichia spp, vancomycin-resistant 
enterococci, and Candida spp, is increased after 
treatment.11,22 Analysis of the Shannon index of α diversity 
indicated that extended-pulsed fidaxomicin enhanced 
microbiota recovery over our study period to a 
significantly higher degree than did vancomycin, 
providing support for extended-pulsed fidaxomicin as a 
microbiota-sparing treatment strategy. This increased 
microbial diversity in patients treated with extended-
pulsed fidaxomicin will be of interest for future studies, 
and suggests a possible mechanistic basis for the reduced 
recurrence rates observed in this study.
More deaths occurred in the vancomycin arm of our 
study, but of greater interest is the higher number of 
deaths among vancomycin recipients after day 27. 
Recurrence has been found to be associated with 
increased mortality by day 90 after hospital discharge.23
A limitation of our study is the absence of standard 
fidaxomicin or extended-pulsed vancomycin arms. 
Although additional treatment arms offer improved 
certainty and depth of information, they also represent a 
major cost driver in clinical trials, which can limit their 
feasibility. Furthermore, vancomycin is considered the 
standard of care for C difficile infection and was therefore 
the most appropriate comparator arm.3 In the present 
setting, data from previous studies provide sufficient 
insight to justify omission of additional treatment arms. 
In-vitro data from a gut model of C difficile infection 
primed with faeces from an older population (aged 
>60 years) do not suggest that incorporating standard and 
extended-pulsed regimens of fidaxomicin would differ in 
terms of efficacy in resolving C difficile infection,14 and our 
observed similarity in clinical response rates at 
day 12 between extended-pulsed fidaxomicin and 
vancomycin supports this hypothesis. This observation, 
combined with data from randomised clinical studies 
showing a recurrence rate of 15·4% or lower for the 
standard fidaxomicin regimen,12,13 suggests outcomes that 
are at least as good for extended-pulsed fidaxomicin 
compared with standard fidaxomicin; however, a future 
indirect treatment comparison of these regimens could be 
of interest to further understand their relative 
effectiveness. Retrospective observational data suggest 
potential efficacy of extended-pulsed vancomycin for 
recurrent C difficile infection.24 However, laboratory studies 
have shown the disruptive effect of vancomycin on gut 
microbiota,25 and such an extended regimen could further 
exacerbate post-treatment gut microbiota dysbiosis.
This study’s definition of C difficile infection recur-
rence—based on worsening symptoms—reflected 
clinical practice, but could be perceived as yielding a low 
threshold for examining recurrence. Nevertheless, 
diagnosis required the investigator to treat for recurrence 
based on their clinical judgment. The absence of blinding 
and insufficient racial diversity in the study population 
might also be considered limitations of this study. 
Furthermore, the study does not provide information on 
the use of extended-pulsed fidaxomicin in patients 
younger than 60 years, or in those with at least three 
C difficile infection recurrences.
Our study has many strengths, including, to our 
knowledge, the first demonstration in a randomised 
clinical trial setting of a C difficile infection recurrence 
rate less than 7% by optimising the delivery of an already 
available antibiotic. This hypothesis-driven study uses 
our understanding of C difficile infection pathogenesis 
and the method of action of fidaxomicin to enhance the 
dosing regimen and improve outcomes in a high-risk 
patient population. 90-day follow-up provided an 
extensive period over which reinfection or recurrence 
could be studied and gave important new data on 
C difficile infection recurrence. Incorporation of a 
microbiota substudy analysis also provided evidence to 
explain and validate observed clinical outcomes.
EXTEND is an uncommon positive superiority 
antibiotic trial, showing an improvement in sustained 
clinical cure of C difficile infection with extended-pulsed 
fidaxomicin and a significant reduction in recurrence 
rates compared with vancomycin treatment, even up to 
day 90, with simultaneous enhanced microbiota 
recovery. Since the extended-pulsed regimen of 
fidaxomicin administers the same number of tablets as 
the standard regimen, the observed benefits are derived 
with no increase in treatment costs and with a similar 
positive safety profile to that of standard-regimen 
vancomycin and fidaxomicin. Furthermore, the 
C difficile recurrence rate of 4% at 30 days after end of 
treatment is, to date, the lowest observed in a 
randomised clinical trial.
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